论文部分内容阅读
血管紧张素转化酶又称为转化酶(CE),亦是肽基二肽基水解酶,激肽酶Ⅱ或“缓激肽酶”。在体内,抑制血管紧张素转化酶可降低血管紧张素Ⅰ(而不是血管紧张素Ⅱ)的升压活性,同时亦增强缓激肽的降压活性。巯甲丙脯氨酸是新的血管紧张素转化酶抑制剂,口服和注射都有效,以相同剂量比较,其作用强度大约是壬肽抗增压素(Teprotide,SQ 20881)的10倍。本药不仅对几种肾性高血压动物模型有快速而显著的降压作用,而且在几种遗传性高血压动物模型包括自发性高血压大鼠,也有降压作用。巯甲丙脯氨酸在体外和体内对血管紧张素转化
Angiotensin-converting enzyme, also known as invertase (CE), is also a peptidyl dipeptidyl hydrolase, kininase II, or “bradykininase.” In vivo, inhibition of angiotensin-converting enzyme reduces the vasopressor activity of angiotensin I (but not angiotensin II) and enhances the hypotensive activity of bradykinin. Captopril is a novel angiotensin-converting enzyme inhibitor that is effective both orally and injections at about 10 times the potency of the non-peptide anti-hypertensive hormone (Teprotide, SQ 20881) at the same dose. The drug is not only rapid and significant antihypertensive effect on several animal models of renal hypertension, but also in several hereditary models of hypertension in spontaneously hypertensive rats, but also antihypertensive effect. Captopril prolongs the conversion of angiotensin in vitro and in vivo